Hologic (NASDAQ:HOLX) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday, January 13th.
A number of other equities research analysts also recently commented on the company. Needham & Company LLC reiterated a “buy” rating and issued a $50.00 target price (up from $48.00) on shares of Hologic in a research report on Tuesday, January 9th. Bank of America upgraded Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price objective on the stock in a research report on Thursday, January 4th. Evercore ISI assumed coverage on Hologic in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $50.00 price objective on the stock. Cowen upgraded Hologic to a “buy” rating and set a $52.00 price objective on the stock in a research report on Wednesday, December 20th. Finally, Goldman Sachs Group raised Hologic from a “buy” rating to a “conviction-buy” rating and upped their target price for the company from $45.00 to $50.00 in a research note on Friday, December 8th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $48.79.
Shares of Hologic (HOLX) traded down $0.54 during trading on Friday, hitting $42.04. The stock had a trading volume of 1,918,462 shares, compared to its average volume of 2,671,250. Hologic has a fifty-two week low of $35.76 and a fifty-two week high of $46.80. The stock has a market capitalization of $12,153.26, a P/E ratio of 15.92, a price-to-earnings-growth ratio of 1.97 and a beta of 0.77. The company has a quick ratio of 0.61, a current ratio of 0.79 and a debt-to-equity ratio of 0.79.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.01. The business had revenue of $802.90 million for the quarter, compared to the consensus estimate of $792.54 million. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The business’s revenue was up 10.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.52 earnings per share. analysts forecast that Hologic will post 2.18 earnings per share for the current year.
In related news, VP Karleen Marie Oberton sold 1,023 shares of the firm’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $39.84, for a total value of $40,756.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Elaine Ullian sold 9,282 shares of the firm’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $40.50, for a total value of $375,921.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 12,099 shares of company stock valued at $487,223. Company insiders own 0.79% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. RKL Wealth Management LLC grew its position in Hologic by 8.6% during the 4th quarter. RKL Wealth Management LLC now owns 25,951 shares of the medical equipment provider’s stock worth $1,109,000 after purchasing an additional 2,066 shares during the period. Public Employees Retirement Association of Colorado grew its position in Hologic by 0.5% during the 4th quarter. Public Employees Retirement Association of Colorado now owns 368,144 shares of the medical equipment provider’s stock worth $15,738,000 after purchasing an additional 1,776 shares during the period. Steinberg Global Asset Management grew its position in Hologic by 9.3% during the 4th quarter. Steinberg Global Asset Management now owns 25,379 shares of the medical equipment provider’s stock worth $1,085,000 after purchasing an additional 2,168 shares during the period. Everence Capital Management Inc. acquired a new stake in Hologic during the 4th quarter worth about $280,000. Finally, Comerica Bank grew its position in Hologic by 26.5% during the 4th quarter. Comerica Bank now owns 96,989 shares of the medical equipment provider’s stock worth $4,161,000 after purchasing an additional 20,341 shares during the period. 97.10% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Hologic (NASDAQ:HOLX) Rating Lowered to Sell at BidaskClub” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/04/hologic-holx-lowered-to-sell-at-bidaskclub.html.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.